Search research articles
Contact Us
Filters
Showing results (321-330 of 350) with videos related to
Page
of 35
Sort By:
Medecine Et Maladies Infectieuses
|
April 16, 2019
Prospective study comparing the conventional and same-day strategies to diagnose pulmonary tuberculosis
A Lopes, F Mougari, D Chopin, et al.
British Journal of Cancer
|
July 16, 2009
Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
C Kahlert, H Weber, C Mogler, et al.
HIV Medicine
|
April 6, 2005
Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study
S Fournier, C Chaffaut, A Maillard, et al.
Antiviral Therapy
|
February 4, 2012
Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
Robert Roomer, Jilling F Bergmann, Andre Boonstra, et al.
HIV Medicine
|
May 18, 2016
Disrupted trabecular bone micro-architecture in middle-aged male HIV-infected treated patients
P Sellier, A Ostertag, C Collet, et al.
Gene
|
May 16, 1998
Characterization of the human gene coding for the swelling-dependent chloride channel ICln at position 11q13.5-14.1 (CLNS1A) and further characterization of the chromosome 6 (CLNS1B) localization
U O Nagl, M Erdel, F Bergmann, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 9, 2011
Prophylactic glycine administration attenuates pancreatic damage and inflammation in experimental acute pancreatitis
G O Ceyhan, A-K Timm, F Bergmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
May 24, 2016
Factor IX inhibitors and anaphylaxis in haemophilia B
I Warrier, B M Ewenstein, M A Koerper, et al.
HIV Medicine
|
June 13, 2002
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy
M Lichterfeld, H D Nischalke, F Bergmann, et al.
Journal of Viral Hepatitis
|
October 31, 2013
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor
J de Bruijne, X V Thomas, S P Rebers, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 350) with videos related to
Sort By:
Page
of 35
Medecine Et Maladies Infectieuses
|
April 16, 2019
Prospective study comparing the conventional and same-day strategies to diagnose pulmonary tuberculosis
A Lopes, F Mougari, D Chopin, et al.
British Journal of Cancer
|
July 16, 2009
Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
C Kahlert, H Weber, C Mogler, et al.
HIV Medicine
|
April 6, 2005
Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study
S Fournier, C Chaffaut, A Maillard, et al.
Antiviral Therapy
|
February 4, 2012
Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
Robert Roomer, Jilling F Bergmann, Andre Boonstra, et al.
HIV Medicine
|
May 18, 2016
Disrupted trabecular bone micro-architecture in middle-aged male HIV-infected treated patients
P Sellier, A Ostertag, C Collet, et al.
Gene
|
May 16, 1998
Characterization of the human gene coding for the swelling-dependent chloride channel ICln at position 11q13.5-14.1 (CLNS1A) and further characterization of the chromosome 6 (CLNS1B) localization
U O Nagl, M Erdel, F Bergmann, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 9, 2011
Prophylactic glycine administration attenuates pancreatic damage and inflammation in experimental acute pancreatitis
G O Ceyhan, A-K Timm, F Bergmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
May 24, 2016
Factor IX inhibitors and anaphylaxis in haemophilia B
I Warrier, B M Ewenstein, M A Koerper, et al.
HIV Medicine
|
June 13, 2002
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy
M Lichterfeld, H D Nischalke, F Bergmann, et al.
Journal of Viral Hepatitis
|
October 31, 2013
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor
J de Bruijne, X V Thomas, S P Rebers, et al.
Page
of 35